Latest Product Launch News

OMG Group posted a 44% increase in Q3 FY26 net sales, hitting a $6 million annual turnover milestone, while launching a dual matcha brand platform and securing national Woolworths distribution for new oat milk protein flavours.

Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.

GCM Corporation finalises exclusive rights to its Very High Density technology, launches its first commercial heat sink products, and expands global prototyping efforts targeting high-growth sectors including EV infrastructure and data centres.

Codan Limited is on track to deliver over 60% growth in EBIT and NPAT for FY26, driven by stronger-than-expected Communications segment revenue and profit margins, alongside robust Minelab performance.

EVE Health Group has begun commercial sales of Libbo, an oral dissolving film for erectile dysfunction, supported by a new digital men’s health platform. The company also expanded its pharmaceutical pipeline and secured $1.3 million in fresh capital to fund ongoing development and commercialization.

PT ANTAM TBK sustained strong operational performance in Q1 2026 with robust gold and nickel sales amid favourable market trends, while pushing forward strategic mineral downstreaming projects including Indonesia's integrated battery ecosystem.

Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.

HighCom Technology secures a nearly A$10 million contract from the Australian Defence for counter small uncrewed aerial systems, marking its first major C-UAS order and reinforcing its defence sector presence.

Elsight’s Halo connectivity platform has gained critical approval on the U.S. Department of War’s DCMA Blue List, enabling rapid military procurement amid a historic US$75 billion drone budget surge.

Barramundi Limited’s portfolio took a heavy hit in Q1 2026, with a 15.4% adjusted NAV decline amid AI disruption anxieties and geopolitical tensions. The fund responded by trimming tech holdings and adding miners BHP and Rio Tinto, betting on copper demand and scale advantages.

Icetana AI reported a 51% year-on-year jump in annual recurring revenue to $2.6 million but faced a $1.2 million net operating cash outflow in Q3 FY26, prompting plans for a capital raise amid expected cash flow improvements.

Bio-Gene Technology is progressing critical toxicology studies for Flavocide with a targeted APVMA submission in March 2027, while forging a strategic partnership to launch Qcide insecticides in Japan by late 2026.